[1]
|
American Thoracic Society and European Respiratory Society (2002) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) Was Adopted by the ATS Board of Directors, June 2001 and by the ERS Executive Committee, June 2001. American Journal of Respiratory and Critical Care Medicine, 165, 277-304.
|
[2]
|
牟相, 赵明栋. 进展性纤维化性间质性肺疾病流行现状及危险因素的研究进展[J]. 临床肺科杂志, 2023, 28(3): 412-415.
|
[3]
|
Wells, A.U., Brown, K.K., Flaherty, K.R., Kolb, M., Thannickal, V.J. and IPF Consensus Working Group (2018) What’s in a Name? That Which We Call IPF, by Any Other Name Would Act the Same. European Respiratory Journal, 51, Article ID: 1800692. https://doi.org/10.1183/13993003.00692-2018
|
[4]
|
白子娜, 李幸彬. 吡非尼酮治疗特发性肺纤维化的研究进展[J]. 中国新药与临床杂志, 2023, 42(9): 560-565.
https://doi.org/10.14109/j.cnki.xyylc.2023.09.03
|
[5]
|
Raghu, G., Remy-Jardin, M., Richeldi, L., et al. (2022) Idi-opathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 205, e18-e47. https://doi.org/10.1164/rccm.202202-0399ST
|
[6]
|
Flaherty, K.R., Wells, A.U., Cottin, V., et al. (2019) Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. The New England Journal of Medicine, 381, 1718-1727. https://doi.org/10.1056/NEJMoa1908681
|
[7]
|
Behr, J., Neuser, P., Prasse, A., et al. (2017) Exploring Efficacy and Safety of Oral Pirfenidone for Progressive, Non-IPF Lung Fibrosis (RELIEF)—A Randomized, Double-Blind, Place-bo-Controlled, Parallel Group, Multi-Center, Phase II Trial. BMC Pulmonary Medicine, 17, Article No. 122. https://doi.org/10.1186/s12890-017-0462-y
|
[8]
|
Maher, T.M., Corte, T.J., Fischer, A., et al. (2020) Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease: A Double-Blind, Randomised, Place-bo-Controlled, Phase 2 Trial. The Lancet Respiratory Medicine, 8, 147-157. https://doi.org/10.1016/S2213-2600(19)30341-8
|
[9]
|
Reiseter, S., Gunnarsson, R., Mogens Aaløkken, T., et al. (2018) Progression and Mortality of Interstitial Lung Disease in Mixed Connective Tissue Disease: A Long-Term Ob-servational Nationwide Cohort Study. Rheumatology (Oxford), 57, 255-262. https://doi.org/10.1093/rheumatology/kex077
|
[10]
|
Zamora-Legoff, J.A., Krause, M.L., Crowson, C.S., Ryu, J.H. and Matteson, E.L. (2017) Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis & Rheumatology, 69, 542-549.
https://doi.org/10.1002/art.39971
|
[11]
|
Nasser, M., Larrieu, S., Si-Mohamed, S., et al. (2021) Progressive Fibrosing Interstitial Lung Disease: A Clinical Cohort (the PROGRESS Study). European Respiratory Journal, 57, Article ID: 2002718.
https://doi.org/10.1183/13993003.02718-2020
|
[12]
|
Hambly, N., Farooqi, M.M., Dvorkin-Gheva, A., et al. (2022) Prevalence and Characteristics of Progressive Fibrosing Interstitial Lung Disease in a Prospective Registry. European Respiratory Journal, 60, Article ID: 2102571.
https://doi.org/10.1183/13993003.02571-2021
|
[13]
|
Adegunsoye, A., Oldham, J.M., Bellam, S.K., et al. (2019) Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Di-verse Interstitial Lung Diseases. Annals of the American Thoracic Society, 16, 580-588. https://doi.org/10.1513/AnnalsATS.201807-443OC
|
[14]
|
Walsh, S.L., Sverzellati, N., Devaraj, A., Keir, G.J., Wells, A.U. and Hansell, D.M. (2014) Connective Tissue Disease Related Fibrotic Lung Disease: High Resolution Computed Tomographic and Pulmonary Function Indices as Prognostic Determinants. Thorax, 69, 216-222. https://doi.org/10.1136/thoraxjnl-2013-203843
|
[15]
|
Kim, H.C., Choi, K.H., Jacob, J. and Song, J.W. (2020) Prog-nostic Role of Blood KL-6 in Rheumatoid Arthritis-Associated Interstitial Lung Disease. PLOS ONE, 15, e0229997. https://doi.org/10.1371/journal.pone.0229997
|
[16]
|
Açıkgöz, S.K., Açıkgöz, E., Şensoy, B., Topal, S. and Aydoğdu, S. (2016) Monocyte to High-Density Lipoprotein Cholesterol Ratio Is Predictive of In-Hospital and Five-Year Mortality in ST-Segment Elevation Myocardial Infarction. Cardiology Journal, 23, 505-512.
|
[17]
|
Chan, A.S. and Rout, A. (2020) Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19. Journal of Clinical Medicine Re-search, 12, 448-453. https://doi.org/10.14740/jocmr4240
|
[18]
|
Xu, Y., He, H., Zang, Y., et al. (2022) Systemic In-flammation Response Index (SIRI) as a Novel Biomarker in Patients with Rheumatoid Arthritis: A Multi-Center Retro-spective Study. Clinical Rheumatology, 41, 1989-2000.
https://doi.org/10.1007/s10067-022-06122-1
|
[19]
|
Chen, Y., Cai, J., Zhang, M. and Yan, X. (2022) Prognostic Role of NLR, PLR and MHR in Patients with Idiopathic Pulmonary Fibrosis. Frontiers in Immunology, 13, Article ID: 882217. https://doi.org/10.3389/fimmu.2022.882217
|
[20]
|
Xue, M., Guo, Z., Cai, C., Sun, B. and Wang, H. (2019) Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia. Respiration, 98, 534-545.
https://doi.org/10.1159/000503689
|
[21]
|
Inoue, Y., Kaner, R.J., Guiot, J., et al. (2020) Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype. Chest, 158, 646-659. https://doi.org/10.1016/j.chest.2020.03.037
|
[22]
|
于娜, 王玮. 间质性肺疾病的治疗进展[J]. 临床内科杂志, 2022, 39(10): 656-658.
|
[23]
|
Rajan, S.K., Cottin, V., Dhar, R., et al. (2023) Progressive Pulmonary Fibrosis: An Expert Group Consensus Statement. European Respiratory Journal, 61, Article ID: 2103187. https://doi.org/10.1183/13993003.03187-2021
|
[24]
|
Dawson, J.K., Quah, E., Earnshaw, B., Amoasii, C., Mudawi, T. and Spencer, L.G. (2021) Does Methotrexate Cause Progressive Fibrotic Interstitial Lung Disease? A Systematic Re-view. Rheumatology International, 41, 1055-1064.
https://doi.org/10.1007/s00296-020-04773-4
|
[25]
|
Kim, J.W., Chung, S.W., Pyo, J.Y., et al. (2023) Methotrexate, Leflunomide and Tacrolimus Use and the Progression of Rheumatoid Arthritis-Associated Interstitial Lung Disease. Rheumatology (Oxford), 62, 2377-2385.
https://doi.org/10.1093/rheumatology/keac651
|
[26]
|
Baughman, R.P. and Grutters, J.C. (2015) New Treatment Strategies for Pulmonary Sarcoidosis: Antimetabolites, Biological Drugs, and Other Treatment Approaches. The Lancet Respiratory Medicine, 3, 813-822.
https://doi.org/10.1016/S2213-2600(15)00199-X
|
[27]
|
王佳琦, 舒强. 吡非尼酮联合免疫抑制剂治疗结缔组织病相关肺间质性病变的研究进展[J]. 山东第一医科大学(山东省医学科学院)学报, 2022, 43(4): 304-310.
|
[28]
|
张凤芹, 窦欣然, 张惠兰. 新型冠状病毒感染后间质性肺疾病[J]. 中国实用内科杂志, 2023, 43(9): 714-717.
|
[29]
|
陈雨田, 丁楅森. 血管分泌因子调控肺再生与纤维化的机制研究进展[J]. 生物医学转化, 2023, 4(3): 25-31.
|
[30]
|
Xu, Z., Li, H., Wen, F., et al. (2019) Subgroup Analysis for Chinese Patients Included in the INPULSIS® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis. Advances in Therapy, 36, 621-631.
https://doi.org/10.1007/s12325-019-0887-1
|
[31]
|
Ogura, T., Inoue, Y., Azuma, A., et al. (2023) Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Sur-veillance in Japan. Advances in Therapy, 40, 1474-1493. https://doi.org/10.1007/s12325-022-02411-y
|
[32]
|
Gagliardi, M., Berg, D.V., Heylen, C.E., et al. (2021) Real-Life Prevalence of Progressive Fibrosing Interstitial Lung Diseases. Scientific Reports, 11, Article No. 2398. https://doi.org/10.1038/s41598-021-03481-8
|
[33]
|
Khanna, D., Albera, C., Fischer, A., et al. (2016) An Open-Label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-Associated Interstitial Lung Disease: The LOTUSS Trial. The Journal of Rheumatology, 43, 1672-1679.
|